Anti-Aging$75–$200

SS-31 (Elamipretide): Dosage, Benefits & Side Effects

By Peptide Assistant Editorial Team · · · 13 sources cited

Overview

SS-31 (Elamipretide, Bendavia, MTP-131) is a mitochondria-targeted tetrapeptide that selectively concentrates in the inner mitochondrial membrane and restores bioenergetic function. It binds to cardiolipin, a phospholipid unique to mitochondria that is essential for electron transport chain efficiency. SS-31 represents a first-in-class approach to treating mitochondrial dysfunction, with clinical trials in heart failure, Barth syndrome, and age-related mitochondrial decline.

Mechanism of Action

SS-31 (D-Arg-Dmt-Lys-Phe-NH2) is a cell-permeable tetrapeptide with an alternating aromatic-cationic motif that allows it to cross membranes and concentrate >1000-fold in the inner mitochondrial membrane within minutes of administration. Its primary target is cardiolipin, an anionic phospholipid exclusively found in the inner mitochondrial membrane that is essential for the structural organization and function of the electron transport chain (ETC) complexes. Cardiolipin normally interacts with cytochrome c to facilitate efficient electron transfer. However, oxidative stress, aging, and disease cause cardiolipin peroxidation, disrupting ETC supercomplex assembly and increasing electron leak (generating more reactive oxygen species in a vicious cycle). SS-31 binds to cardiolipin and stabilizes its interaction with cytochrome c, restoring efficient electron flow through Complex III and IV. This reduces electron leak, decreases mitochondrial ROS production, and improves ATP synthesis. SS-31 was first described as an antioxidant whose dimethyltyrosine residue scavenges ROS; later work attributes its main effect to binding cardiolipin, which limits excess ROS generation at the source by optimizing ETC function. It also protects against mitochondrial permeability transition pore opening, preventing apoptotic signaling.

SS-31 (Elamipretide) Benefits: What the Research Shows

  • EMBRACE STEMI trial (2016, European Heart Journal): SS-31 (elamipretide) did not reduce infarct size or improve other outcomes in patients with acute ST-elevation MI
  • TAZPOWER trial in Barth syndrome (12 patients) missed both primary endpoints in its placebo-controlled phase; walk distance and knee extensor strength improved in the open-label extension, and the strength gain was the basis for FDA accelerated approval in 2025
  • Siegel et al. (2013, Aging Cell) demonstrated SS-31 reversed age-related mitochondrial dysfunction and improved skeletal muscle performance in old mice
  • SS-31 decreased ROS production in isolated mitochondria, and in a randomized trial of 39 older adults a single infusion raised muscle ATP production capacity without improving fatigue resistance
  • Studies in renal ischemia-reperfusion models showed SS-31 prevented acute kidney injury and preserved tubular function
  • Tarantini et al. (2018, Aging Cell) showed SS-31 improved cerebrovascular endothelial function and cognition in aged mice

SS-31 (Elamipretide) Dosage

  • Clinical trial doses (heart failure): a single 4-hour IV infusion of 0.005–0.25 mg/kg/hour, or 4 mg or 40 mg SC daily for 28 days
  • Barth syndrome trials: 40 mg SC daily for up to 168 weeks
  • Research protocols: 0.5–5 mg/kg subcutaneous injection daily
  • Some anti-aging protocols use 1–5 mg subcutaneous injection daily or every other day
  • No established oral dosing — peptide requires parenteral administration
  • Cycle: the Barth syndrome extension study used continuous daily dosing for more than 3 years in 8 patients; the label warns of injection site reactions and hypersensitivity reactions
Peptide calculator: get your dose in syringe units →

Disclaimer: Dosing information is compiled from research literature and community protocols for educational purposes only. This is not medical advice. Always consult a qualified healthcare provider before starting any peptide protocol.

SS-31 (Elamipretide) Side Effects & Safety

Known Side Effects

  • Injection site reactions (redness, pain) are the most commonly reported side effect in clinical trials
  • Headache reported in some trial participants
  • Mild GI symptoms (nausea) at higher doses
  • Clinical trials have shown a generally favorable tolerability profile
  • No significant organ toxicity observed in studies up to 168 weeks
  • Theoretical concern about altering mitochondrial dynamics in rapidly dividing cells

Safety Profile

SS-31 (elamipretide) has undergone multiple Phase I–III clinical trials with a favorable safety record. The Barth syndrome TAZPOWER extension study provided long-term safety data over 168 weeks of daily SC dosing, though in only 10 patients. The most common adverse events are injection site reactions and headache. The label warns of hypersensitivity reactions, including serious allergic reactions, and notes that eosinophil counts often rose temporarily without symptoms. The compound does not appear to accumulate or cause tolerance with chronic use. In 2025 the FDA approved elamipretide (Forzinity) under accelerated approval to improve muscle strength in patients with Barth syndrome weighing at least 30 kg; continued approval may depend on a confirmatory trial. It is not approved for any other indication. The label's only contraindication is serious hypersensitivity to elamipretide or its ingredients, and the dose is halved in severe kidney impairment.

What to Expect

Week 1–2: Effects on mitochondrial function begin immediately at the cellular level but subjective improvements are subtle. Some users report improved energy levels and exercise recovery. Week 2–4: Improved exercise tolerance and reduced post-exertion fatigue become more noticeable. Cellular energy production improves. Week 4–8: Sustained energy improvements, better cardiovascular endurance, and improved recovery from physical and mental exertion. In the open-label extension of the Barth syndrome trial (10 patients), 6-minute walk distance improved, but placebo-controlled trials in Barth syndrome and mitochondrial myopathy found no improvement in walk distance. Week 8+: Continued optimization of mitochondrial function. In aging populations, benefits may include improved cognitive clarity, vascular function, and physical performance. Long-term users report sustained benefits without tolerance.

Common Stacks

Storage & Handling

Store lyophilized SS-31 at -20°C for long-term storage (2+ years). At 2–8°C, stable for up to 12 months. Reconstitute with sterile water or bacteriostatic water; reconstituted solution should be stored at 2–8°C and used within 14–28 days. Protect from light. The peptide is relatively stable but sensitive to repeated freeze-thaw cycles.

Pricing & Available Variants

$75 – $200price range
10mg25mg50mg

Prices sourced from peptides.gg marketplace. Prices may vary.

References

  1. Forzinity (elamipretide) injection, for subcutaneous use: prescribing information. Stealth BioTherapeutics, via DailyMed. 2026.
  2. Reid Thompson W, Hornby B, Manuel R, et al. A phase 2/3 randomized clinical trial followed by an open-label extension to evaluate the effectiveness of elamipretide in Barth syndrome, a genetic disorder of mitochondrial cardiolipin metabolism. Genet Med. 2021.
  3. Thompson WR, Manuel R, Abbruscato A, et al. Long-term efficacy and safety of elamipretide in patients with Barth syndrome: 168-week open-label extension results of TAZPOWER. Genet Med. 2024.
  4. Karaa A, Bertini E, Carelli V, et al. Efficacy and Safety of Elamipretide in Individuals With Primary Mitochondrial Myopathy: The MMPOWER-3 Randomized Clinical Trial. Neurology. 2023.
  5. Butler J, Khan MS, Anker SD, et al. Effects of Elamipretide on Left Ventricular Function in Patients With Heart Failure With Reduced Ejection Fraction: The PROGRESS-HF Phase 2 Trial. J Card Fail. 2020.
  6. Daubert MA, Yow E, Dunn G, et al. Novel Mitochondria-Targeting Peptide in Heart Failure Treatment: A Randomized, Placebo-Controlled Trial of Elamipretide. Circ Heart Fail. 2017.
  7. Gibson CM, Giugliano RP, Kloner RA, et al. EMBRACE STEMI study: a Phase 2a trial to evaluate the safety, tolerability, and efficacy of intravenous MTP-131 on reperfusion injury in patients undergoing primary percutaneous coronary intervention. Eur Heart J. 2016.
  8. Szeto HH. First-in-class cardiolipin-protective compound as a therapeutic agent to restore mitochondrial bioenergetics. Br J Pharmacol. 2014.
  9. Zhao K, Zhao GM, Wu D, et al. Cell-permeable peptide antioxidants targeted to inner mitochondrial membrane inhibit mitochondrial swelling, oxidative cell death, and reperfusion injury. J Biol Chem. 2004.
  10. Siegel MP, Kruse SE, Percival JM, et al. Mitochondrial-targeted peptide rapidly improves mitochondrial energetics and skeletal muscle performance in aged mice. Aging Cell. 2013.
  11. Roshanravan B, Liu SZ, Ali AS, et al. In vivo mitochondrial ATP production is improved in older adult skeletal muscle after a single dose of elamipretide in a randomized trial. PLoS One. 2021.
  12. Szeto HH, Liu S, Soong Y, et al. Mitochondria-targeted peptide accelerates ATP recovery and reduces ischemic kidney injury. J Am Soc Nephrol. 2011.
  13. Tarantini S, Valcarcel-Ares NM, Yabluchanskiy A, et al. Treatment with the mitochondrial-targeted antioxidant peptide SS-31 rescues neurovascular coupling responses and cerebrovascular endothelial function and improves cognition in aged mice. Aging Cell. 2018.

Related Peptides

Track SS-31 (Elamipretide) in Your Protocol

Log your SS-31 (Elamipretide) doses, track consistency, and monitor your protocol with Peptide Assistant — completely free.

Start Tracking Free